StockData
Vertex Pharmaceuticals Inc logo

Vertex Pharmaceuticals Inc

VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 15/3036% above fair value
$553.15−5.73 (-1.03%)

Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –

Vertex Pharmaceuticals Total pre-tax Non-GAAP adjustments by Quarter

Total pre-tax Non-GAAP adjustments (SBC, intangible amortization, contingent consideration & acquisition costs, $M) ($M)

QuarterlyAnnual

Vertex Pharmaceuticals Total pre-tax Non-GAAP adjustments: $139M in Q2 2026, down 17.4% from a year earlier.

Latest, Q2 2026
139
Period ended Jun 30, 2026
Change on a year earlier
-17.4%
169 in Q2 2025
History
34 quarters
Since Q1 2018
Sources
29
Documents cited below

Where the Q2 2026 figure comes from

“|| Total non-GAAP adjustments to pre-tax income | 139.2 | 168.6 | 313.4 | 736.5”

Source: Form 8-K (ex-991_q22026.htm, filed 2026-08-03) ↗

Reported in Form 8-K EX-99.1 Earnings Releases (GAAP to Non-GAAP Reconciliations).

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedTotal pre-tax Non-GAAP adjustments (SBC, intangible amortization, contingent consideration & acquisition costs, $M) ($M)Year on yearSource
Q2 2026Jun 30, 2026139-17.4%Form 8-K (ex-991_q22026.htm, filed 2026-08-03) ↗
Q1 2026Mar 31, 2026174-69.3%Form 8-K (ex-991_q12026.htm, filed 2026-05-04) ↗
Q4 2025Dec 31, 2025157-12.5%Form 8-K (ex-991_q42025.htm, filed 2026-02-12) ↗
Q3 2025Sep 30, 2025201-0.2%Form 8-K (ex-991_q32025.htm, filed 2025-11-03) ↗
Q2 2025Jun 30, 2025169-55.8%Form 8-K (ex-991_q22026.htm, filed 2026-08-03) ↗
Q1 2025Mar 31, 2025568+153.8%Form 8-K (ex-991_q12026.htm, filed 2026-05-04) ↗
Q4 2024Dec 31, 2024180+10.0%Form 8-K (ex-991_q42025.htm, filed 2026-02-12) ↗
Q3 2024Sep 30, 2024202+42.8%Form 8-K (ex-991_q32025.htm, filed 2025-11-03) ↗
Q2 2024Jun 30, 2024381+212.8%Form 8-K (ex-991_q22025.htm, filed 2025-08-04) ↗
Q1 2024Mar 31, 2024224+91.4%Form 8-K (ex-991_q12025.htm, filed 2025-05-05) ↗
Q4 2023Dec 31, 2023163+32.9%Form 8-K (ex-991_q42024.htm, filed 2025-02-10) ↗
Q3 2023Sep 30, 2023141-3.3%Form 8-K (ex-991_q32024.htm, filed 2024-11-04) ↗
Q2 2023Jun 30, 2023122-26.0%Form 8-K (ex-991_q22023.htm, filed 2023-08-01) ↗
Q1 2023Mar 31, 2023117-41.9%Form 8-K (ex-991_q12024.htm, filed 2024-05-06) ↗
Q4 2022Dec 31, 2022123+14.4%Form 8-K (ex-991_q42023.htm, filed 2024-02-05) ↗
Q3 2022Sep 30, 2022146+141.7%Form 8-K (ex-991_q32023.htm, filed 2023-11-06) ↗

Cite this data

StockData. (2026). Vertex Pharmaceuticals Total pre-tax Non-GAAP adjustments ($M), quarterly Q1 2018–Q2 2026 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/nongaap-pretax-adj

See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.